Fredun Pharmaceuticals Ltd

Price story Before the numbers, the tape. A stock price moves through four repeating seasons: a flat base (stage 1), an advance (2), a top (3), a decline (4). Where the price sits in that cycle frames everything below.

Fredun Pharmaceuticals Ltd trades at ₹955, in a confirmed uptrend and 55 weeks into that stage. That is +48.0% against its own 200-day average. It sits at 9% of a 52-week range of ₹770 to ₹2,805. On relative strength it has been ahead of the NIFTY 500 on a trailing-13-week view for 1 straight week.

Today the stock is in a confirmed uptrend — week 55 of stage 2, confirmed. At ₹955 it trades +48.0% versus its 200-day average and sits at 9% of its 52-week range (₹770–₹2,805).

Against the market, two honest reads. Cumulative: over the last 10.3 years the stock moved +7,542% while the NIFTY 500 moved +266% — ahead of the index over the full window. Recent form: on a trailing-13-week view the stock has been ahead for 1 straight week — the ribbon below is that same metric, week by week.

What would end the trend, mechanically: two Friday closes in a row below the 200-day line. That is the exit rule — no debates.

→ The trend is one thing; the bill is another. Are you paying up for it? Next: the P/E sits at the 96th percentile of its own range.

Valuation P/E is the price of ₹1 of annual profit: how many rupees the market pays for each rupee the company earns in a year.

Fredun Pharmaceuticals Ltd trades at 45.4× P/E, at the pricey end of its own range (96th percentile). Its long-run median P/E is 33.5×, measured across 1.2 years of weekly readings. This places the multiple against the stock’s own record, and says nothing about what the business is worth.

Today's P/E of 45.4× is at the pricey end of its own range (96th percentile), against a long-run median of 33.5× measured over 1.2 years of weekly readings. This is a comparison against the stock's own history — not a claim about what it is worth.

Why the multiple sits where it does: over the past year annual EPS moved +43.1% against a +3.9% price move — earnings outran the price, pushing the multiple DOWN its own range.

Put together: the multiple is full against its own past, so the story rests on the earnings line underneath it, not the multiple.

→ Cheap or dear rides on the earnings. Are they actually growing? Next: the fundamental stage — where the business sits in its arc, and how growth has compounded.

Stage: No read Every business sits somewhere on a fundamental arc, and this page names the spot before anything else. The last twelve quarters of revenue, profit and EPS growth — plus the return the business earns on its capital — are read as curves: Deteriorating (the curves are falling), Turning around (a trough has just formed and the last few quarters lift off it), Improving (the climb off the trough is sustained), Consistent (steadily positive with healthy returns), Topping out (still high but decelerating from the peak). When the curves genuinely disagree the read is Mixed; too little history is No read. CAGR (compound annual growth rate) is the smooth yearly pace that turns the starting value into the latest one — the fairest way to compare growth across different time spans. Read the columns together: if the 1-year number towers over the 10-year, recent growth is running hotter than the long-run trend. A dash means that window is not held, or the base year was a loss (where a growth rate is not meaningful).

Fredun Pharmaceuticals Ltd reads as no read on its fundamental arc. Under eight usable quarters on the growth trio — not enough history for an honest trajectory read.

Why it matters: with too little history, an honest page says so instead of guessing a trajectory.

Return readings here are annual, not quarterly — read as level and direction only; they can confirm the growth curves but never drive the stage on their own.

Fewer than eight usable quarters on the growth curves — this page will not guess a trajectory from a stub of history.

→ The stage names the trajectory. Next: the revenue line that produces it, quarter by quarter.

4-Factor Sector Score

45.9/100 — rank 23 of 43 in Pharma - Formulators · 50% evidence confidence

Fredun Pharmaceuticals Ltd scores 45.9 out of 100 against the 43 companies it is compared with in Pharma - Formulators, ranking 23. Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral.

The four contributions add to the total exactly: 19 + 12.8 + 9.3 + 4.8 = 45.9. This is the SAME number shown on the sector comparison — it is computed once, for the whole peer set, and read here.

What would change it: The read weakens if profit growth turns negative or margin improvement reverses while sector-relative strength deteriorates.

Revenue Revenue is the top line: everything the company billed its customers in the period.

Fredun Pharmaceuticals Ltd reported ₹213 Cr of revenue in the Mar 26 quarter, +27.5% year on year. Over 1 years it has compounded at 39.9% a year. The last full year, FY26, came in at ₹635 Cr. The last four reported quarters add to ₹639 Cr.

Fredun Pharmaceuticals Ltd reported ₹213 Cr of revenue in the Mar 26 quarter, +27.5% year on year. Over 1 years it has compounded at 39.9% a year. The last full year, FY26, came in at ₹635 Cr. The last four reported quarters add to ₹639 Cr.

FY26 revenue came in at ₹635 Cr (+39.9% on the year), capping 1 years at 39.9% compound. The latest quarter (Mar 26) printed ₹213 Cr, +27.5% year on year.

Pace check: the last four quarters averaged +27.5% growth against the decade's 39.9% — the current year is running slower than its own long-run rate.

→ Revenue grew — did margins hold as it scaled? Next: 14.0% this quarter (+4.0 pp YoY).

Operating margin Operating margin is what is left of every ₹100 of sales after running the business, before interest and tax. It is the cleanest read on pricing power and cost control.

Fredun Pharmaceuticals Ltd's operating margin is 14.0% in the Mar 26 quarter, +4.0 percentage points against the same quarter a year ago.

Fredun Pharmaceuticals Ltd's operating margin is 14.0% in the Mar 26 quarter, +4.0 percentage points against the same quarter a year ago.

The latest quarter's operating margin is 14.0%, +4.0 pp against the same quarter a year ago. Across 2 fiscal years the operating margin has ranged 12.0%–14.0%.

Why the margin moved: operating margin went +3.3 pp year on year while gross margin went +2.0 pp — the gain came mostly from the gross line: input costs and pricing.

→ Margins held — did that reach the bottom line? Next: profit +83.3% in the latest quarter.

Net profit Net profit is what survives every cost, interest and tax — the number EPS, dividends and book value all grow from.

Fredun Pharmaceuticals Ltd earned ₹11.0 Cr of net profit in the Mar 26 quarter, +83.3% year on year. Full-year FY26 profit was ₹33.0 Cr. The 1-year compound rate is 65.0%. That is 5.2% of the quarter's revenue. The same quarter a year earlier earned ₹6.0 Cr.

Fredun Pharmaceuticals Ltd earned ₹11.0 Cr of net profit in the Mar 26 quarter, +83.3% year on year. Full-year FY26 profit was ₹33.0 Cr. The 1-year compound rate is 65.0%. That is 5.2% of the quarter's revenue. The same quarter a year earlier earned ₹6.0 Cr.

Mar 26 profit was ₹11.0 Cr, +83.3% year on year. On the full year, FY26 printed ₹33.0 Cr (+65.0%), and the 1-year compound rate is 65.0%.

→ Profit rose — but did the cash follow? Next: −9% of the last 2 years' profit arrived as cash.

Cash flow — the router The P&L says what was earned; the cash-flow statement says what actually arrived. Operating cash flow (CFO) against profit is the cleanest lie detector in the accounts.

Over the last 2 fiscal years −9% of Fredun Pharmaceuticals Ltd's reported profit arrived as operating cash — a gap worth watching. In FY26 that was ₹12.0 Cr of operating cash against ₹33.0 Cr of profit. After ₹73.0 Cr of capital spending, ₹−61.0 Cr was left as free cash.

FY26: operating cash of ₹12.0 Cr against reported profit of ₹33.0 Cr, leaving free cash of ₹−61.0 Cr after ₹73.0 Cr of capital spending. Across the last 2 fiscal years the conversion rate is −9% of profit.

Cash-flow readings here are annual — that is the resolution our series carries, so this section moves once a year.

🚨 Why conversion sits at −9%: the cash cycle tightened 47 days between FY25 and FY26 — cash that used to wait in the cycle now reaches the bank sooner. Less than 70% of profit arriving as cash is the thing to watch on this page.

Router verdict: the bigger cash user is investment — capital spending ran 9.1× depreciation over three years, so the next section's job is to check what that build-out is buying.

→ So follow the cash to where it goes. Next: ₹73.0 Cr of building over 1 years.

Where the cash goes Working capital is the cash tied up between paying suppliers and getting paid: debtor days (customers owe), inventory days (stock waits), and the cash conversion cycle (the whole loop, in days of sales).

Fredun Pharmaceuticals Ltd's cash conversion cycle runs 201 days in FY26, down from 248 days in FY25. Capital spending ran ₹73.0 Cr over the last 1 years. At FY26 sales of ₹635 Cr each day of that cycle holds about ₹1.7 Cr, so roughly ₹350 Cr sits inside the business at any moment.

FY26: debtors at 53 days, inventory at 219 days — roughly 7.2 months of stock waiting to sell; that is where the cash sits while it waits — for a full cycle of 201 days, tighter than FY25's 248.

The full loop: cash goes out to suppliers and production on day 0; stock waits 219 days to sell; customers pay about 53 days after that; and suppliers themselves are paid at 71 days — netting out to the 201-day cycle.

In money terms: at FY26 sales of ₹635 Cr, each day of the cycle holds about ₹1.7 Cr — so the 201-day loop keeps roughly ₹350 Cr sitting inside the business at any moment.

On the investment side: capital spending of ₹73.0 Cr over the last 1 fiscal years against ₹8.0 Cr of depreciation — the company is building well ahead of wear-and-tear. Capital work-in-progress stands at ₹0.0 Cr (FY26) — capacity paid for but not yet earning.

The synthesis: the cash is going into capacity, not disappearing into the cycle — the question becomes whether the new capacity earns.

→ Does all this activity actually earn its cost of capital? Next: ROCE is 21%.

Return on capital Return on capital employed (ROCE) is the profit the whole business earns on all the money in it — equity and debt together. It is the single best test of whether growth creates value or just size.

Fredun Pharmaceuticals Ltd earns a ROCE of 21% in FY26. A return-on-invested-capital spread against the cost of capital is not computable from what is held here. The wiring behind it is 5.2% net margin on 0.99× asset turns.

FY26 ROCE is 21%.

Why the return is what it is — the wiring (FY26): 5.2% net margin × 0.99× asset turns × 2.31× balance-sheet leverage ≈ 11.9% on equity. Margin does its share; leverage is a meaningful part of the equation.

→ Returns like these — is the balance sheet borrowing to make them? Next: debt-to-equity is 0.80.

Debt Debt-to-equity says how much of the business is funded by borrowings; interest cover says how many times operating profit pays the interest bill. Low and high, respectively, is the safe corner.

Fredun Pharmaceuticals Ltd carries ₹222 Cr of borrowings against ₹278 Cr of equity in FY26, a debt-to-equity of 0.80. Operating profit covers the interest bill 2×. Over 1 years borrowings went from ₹167 Cr to ₹222 Cr. Capital spending ran ₹73.0 Cr across the last 1 of those years.

FY26: borrowings of ₹222 Cr against equity of ₹278 Cr — a debt-to-equity of 0.80. Operating profit covers the interest bill 2×. Over 1 years borrowings went from ₹167 Cr to ₹222 Cr while capital spending ran ₹73.0 Cr in just the last 1 — part of the build-out is riding on borrowed money.

→ Who owns this, and are they adding or leaving? Next: Promoters cut 4.4 points over 8 quarters.

Ownership Who owns the stock, quarter by quarter: promoters (the controlling owners), foreign and domestic institutions, and the public. Steady accumulation by people close to the numbers is a signal; a quiet register is also an answer.

Promoters cut 4.4 points of Fredun Pharmaceuticals Ltd over 8 quarters, the biggest move on the register. That takes promoters to 44.6% of the company. Domestic institutions moved +1.3 points over the same window, to 2.9%. The register is read on the four disclosed classes only; nothing is inferred between filings.

The register over the last two years — Promoters: −4.4 points over 8 quarters to 44.6%; Domestic institutions: +1.3 points over 8 quarters to 2.9%; Foreign institutions: +1.1 points over 8 quarters to 1.1%.

🚨 Why the register moved: promoters drove it (−4.4 points), absorbed on the other side by domestic institutions (+1.3 points) — distribution into the market’s bid.

→ One last check: does the safety math agree? Next: the balance-sheet safety line.

Safety line The Z-score estimates how far a company sits from balance-sheet distress — above roughly 3 is safe, below roughly 1.8 is the danger zone. It was built for manufacturers, so it is not applied to banks and lenders.

Fredun Pharmaceuticals Ltd: the Z-score is not available for this stock, so we say so rather than invent one. It is a distance-to-distress estimate from the balance sheet, not a forecast of failure. The debt, cash-flow and return sections above carry the balance-sheet evidence this page does hold, and each of them states its own reporting date.

The safety line in one sentence: the Z-score is not available for this stock, so we say so rather than invent one.

Frequently asked questions